Related Experiment Video
Updated: May 27, 2025
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
14.8K
Predicting Resistance to Small Molecule Kinase Inhibitors
Anu Nagarajan1, Katherine Amberg-Johnson1, Evan Paull1
1Schrödinger, New York, New York 10036, United States.
Journal of Chemical Information and Modeling
|February 20, 2025
Summary
This study introduces a computational method combining genetic models and physics-based calculations to predict drug resistance mutations. The approach successfully identified key mutations for EGFR inhibitors, aiding in the development of more durable cancer treatments.
Area of Science:
- Computational biology
- Drug discovery
- Molecular modeling
Background:
- Drug resistance, particularly to small molecule inhibitors (SMIs), poses a significant challenge in treating cancers and infectious diseases.
- Predicting on-target resistance mutations is crucial for developing effective and durable therapies.
Purpose of the Study:
- To develop and validate a novel computational workflow for predicting on-target resistance mutations to small molecule inhibitors.
- To integrate genetic models with physics-based calculations for enhanced prediction accuracy.
Main Methods:
- Developed a computational workflow integrating the RECODE genetic model with alchemical free energy perturbation (FEP+) calculations.
- RECODE prioritizes probable amino acid changes based on cancer-specific mutation patterns.
- Physics-based calculations assessed the impact of mutations on protein stability, substrate binding, and inhibitor binding.
Main Results:
- The workflow accurately predicted known binding site mutations for gefitinib (4/11) and osimertinib (7/19), including clinically relevant T790M and C797S mutations.
- Successfully identified key resistance mutations in epidermal growth factor receptor (EGFR) inhibitors used for non-small cell lung cancer (NSCLC).
Conclusions:
- The integrated computational approach demonstrates significant potential for predicting small molecule inhibitor resistance mutations.
- This methodology can be extended to other kinases and target classes, facilitating the design of next-generation inhibitors with improved clinical durability.
